NCT02580708 is a Phase 1, PHASE2 clinical trial of Rociletinib in Non-small Cell Lung Cancer, sponsored by Clovis Oncology, Inc..

Who is sponsoring NCT02580708?

NCT02580708 is sponsored by Clovis Oncology, Inc..

What drugs are being tested in NCT02580708?

Interventions in NCT02580708: Rociletinib, Trametinib.

What condition does NCT02580708 study?

NCT02580708 studies Non-small Cell Lung Cancer.

Is NCT02580708 still recruiting?

NCT02580708 is currently terminated. Last updated 2 October 2018.

Last reviewed 2018-10-02 · How we verify

NCT02580708

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated Phase 1, PHASE2 Last updated 2 October 2018

What this trial tests

Phase 1, PHASE2 trial testing Rociletinib in Non-small Cell Lung Cancer in 7 participants. Terminated before completion.

Timeline

30 September 2015

Primary endpoint
5 May 2016

27 June 2016

Quick facts

Lead sponsor	Clovis Oncology, Inc.
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	30 September 2015
Primary completion	5 May 2016
Estimated completion	27 June 2016
Sites	4 locations across United States

Drugs / interventions tested

Rociletinib — full drug profile →
Trametinib (trametinib) — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Clovis Oncology, Inc. — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.
Xu J, Wang J, Zhang S. · · 2017 · cited 38× · PMID 29163853 · DOI 10.18632/oncotarget.21164
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC, Lin CC, Lee JH, Yang JC. · · 2016 · cited 36× · PMID 27912760 · DOI 10.1186/s12929-016-0305-9
The pharmacogenomics of drug resistance to protein kinase inhibitors.
Gillis NK, McLeod HL. · · 2016 · cited 17× · PMID 27620953 · DOI 10.1016/j.drup.2016.06.008

Verify or expand the search:

Other trials of Rociletinib

Trials testing the same drug.

NCT02630186 — A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Meta · Phase 1, PHASE2 · terminated
NCT02147990 — Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer · Phase 2 · terminated
NCT01526928 — Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal · Phase 1, PHASE2 · terminated
NCT02547675 — Rociletinib (CO-1686) USA Expanded Access Program · no longer available

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Clovis Oncology, Inc. trials

Trials by the same sponsor.

NCT02630186 — A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Meta · Phase 1, PHASE2 · terminated
NCT02202746 — A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastati · Phase 2 · terminated
NCT02147990 — Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer · Phase 2 · terminated
NCT01526928 — Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal · Phase 1, PHASE2 · terminated
NCT02547675 — Rociletinib (CO-1686) USA Expanded Access Program · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02580708 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clovis Oncology, Inc.
Last refreshed: 2 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02580708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing